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Introduction
Over the past two decades, there have been multiple attempts by
government to fund comparative effectiveness research (CER) in
the US. Unfortunately, these efforts have been stymied, typically
by Congress refusing to commit the scale of funding necessary to
address the magnitude of clinical problems for which such infor-
mation would inﬂuence practice. As a result, to date, the drug
and device regulatory approval system has been the primary
driver of the type of evidence that is generated to support a
product launch. The great majority of evidence generated for
regulatory approval could not be construed as comparative effec-
tiveness research.
In an unprecedented move, new legislation passed by Con-
gress known as the American Recovery and Reinvestment Act
(ARRA) that was aimed at overcoming the economic downturn,
includes $1.1 billion dollars to support CER in the US; the size of
this budget is orders of magnitude more than has ever been
committed to this ﬁeld. These funds are being distributed via
three main routes: the Ofﬁce of the Secretary of Health and
Human Services, the director of the National Institutes of Health,
and the Agency for Healthcare Research and Quality.
Because of the ongoing debate around what constituted com-
parative effectiveness research, the ARRA legislation speciﬁcally
called on the Institute of Medicine (IOM) to deﬁne comparative
effectiveness and to set CER priorities. Ironically, comparative
effectiveness research funds were already ﬂowing out of the
National Institutes of Health (NIH) before the IOM published its
deﬁnition of CER (subsequently published August 4, 2009), or
the IOM priority areas established. The IOM Committee
working deﬁnition of CER is given below:
CER is the generation and synthesis of evidence that com-
pares the beneﬁts and harms of alternative methods to
prevent, diagnose, treat, and monitor a clinical condition, or
to improve the delivery of care. The purpose of CER is to
assist consumers, clinicians, purchasers, and policymakers to
make informed decisions that will improve health care at
both the individual and population levels (adapted from [1])
The NIH had set its own priorities and released more than
$200 million dollars to fund several hundred research programs.
In light of the debate about what CER was, it is noteworthy
that the IOM deﬁnition of CER includes consumers and purchas-
ers as beneﬁciaries of the research, implying that costs or cost-
effectiveness are valid metrics of comparison.
Regulation of Drugs and Devices in the US
The process of regulation that brings new drugs and devices to
market illustrates the reason why many researchers and policy-
makers felt that comparative effectiveness research was needed.
One of the ﬁrst decisions the Food and Drug Administration
(FDA) makes about a new technology is whether it is a drug or
a device as deﬁned in the Food and Drug and Cosmetic Act
(Table 1). The regulatory requirements set by the FDA are quite
different for these categories. After determining whether a
product is a drug or device, meeting these requirements is key to
accessing the health-care market.
It is important to note that neither of these deﬁnitions
requires that a drug or device show equivalence or superiority to
best alternative care. Indeed, most products come to market with
studies comparing them to placebo or best supportive care (i.e.,
care that does not intend to cure the condition).
Drug Labeling and Promotion
The drug label (stated indication) drives the use of drugs and
devices in the US; it is limited to proven efﬁcacy and safety.
Although drugs may be prescribed off-label, by law, the drug or
device cannot be promoted beyond the bounds of what is on the
label.
Drug Development
Drug development is a very long and costly process that starts
from basic research, preclinical and the investigational new drug
application, and goes from Phase One to Phase Three (often
called “pivotal”) clinical trials. Phase One clinical trials are the
ﬁrst human trials of a new drug. They typically involve testing
the drug in a small number of healthy individuals to determine
whether it is metabolized as expected, and what side effects
occur. Phase Two trials are then conducted to test drug efﬁcacy.
They typically involve a small number of patients and are also
often designed to establish an appropriate dosage, as well as to
continue to build the safety proﬁle. Phase Three trials are large
controlled trials that assess safety and efﬁcacy in the general
patient population. They typically involve one or more large
cohorts of patients, with international representation. The com-
parator may be a placebo, an active comparator, or current
standard of care.
If a drug shows signiﬁcant clinical improvement in outcomes
and reasonable safety in two double-blind, controlled studies, the
FDA may grant approval to market the drug, after which the
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product is launched. A typical time horizon to get from concept
to approval is 8 to 10 years, although it may be longer. The
estimated cost of bringing a new chemical entity to the market,
including the legislated fee for the FDA review, is in the order of
about $800 million dollars [2].
Limitations of the Regulatory Process for Drugs
Trial-based evaluations of safety and efﬁcacy have several limi-
tations for clinicians and other decision-makers. First, the trial
based populations typically represents a select patient population
rather than patients in the “real world;” as such, the results may
not be generalizable. Second, as noted above, the comparator is
typically not the best alternative treatment. Placebo or the
weakest alternatives tend to be selected, rather than standard of
care. Other limitations are that study endpoints are typically
short-term, and the studies are often underpowered to determine
population-wide safety endpoints.
Device Development
The FDA classiﬁes devices that are submitted to them for
approval into three classes:
1. Class I: Low-risk devices; e.g., band-aids, crutches. These
types of devices are subject to general controls with low
stringency.
2. Class II: Medium-risk devices; e.g., syringes. These types of
devices are subject to general controls plus additional
special controls that are often related to manufacturing
processes (quality control).
3. Class III: High-risk devices; e.g., drug-eluting stents. These
types of devices are subject to general controls and a system
of premarket approval (PMA) that requires evidence
generation.
There are two routes to getting a device approved through the
FDA; premarket notiﬁcation or 510(k), and premarket approval
(PMA). The vast majority of devices get approved through the
510(k) process. PMA only applies to Class III devices. If it is
permitted by the FDA, device manufacturers much prefer the
510(k) route, as it simply requires proving “substantial equiva-
lence” to a currently marked device, and therefore is much less
costly and faster than PMA (Table 2).
Premarket Notiﬁcation, 510 (k)
The 510(k) process requires the manufacturer to demonstrate
that the new device is substantially equivalent to an existing
device that is already marketed in the US, with substantial
equivalence being deﬁned as meaning that the device is as safe
and as effective as the existing device. It is worth noting that
setting the regulatory standard at proving that a new device is as
good as existing technology creates somewhat of a conundrum
for purchasers and clinicians, as after gaining approval, the
manufacturer may market their device as the best new thing.
PMA
This process applies when the FDA decides that the technology is
not substantially equivalent to an existing technology because it
is a novel entity; as such, it is considered to be of high-risk. In
these cases, the manufacturer must prove reasonable assurance of
safety and effectiveness. As shown in Table 2, the standard fee for
PMA is much higher and the review time much longer than for
510(k). However, the major expense for the manufacturer is in
cases where the FDA requires a prospective study (although not
necessarily controlled) that demonstrate the safety and effective-
ness of the device.
Limitations of the Regulatory Process for Devices
There are a number of limitations of the regulatory process for
devices. First, there is currently no requirement by the FDA for
randomized controlled trials of devices versus best alternative
care. In fact, the vast majority go through the 510(k) process,
which requires a comparison to an older device, but no trial of
any sort. A second very important limitation is that operator skill
is not part of the regulatory process. Evidence suggests that
variations in operator skill can lead to signiﬁcantly different
patient outcomes. As a well-described example, perioperative
mortality associated with lung volume reduction surgery with
bovine pericardium (the device) was reduced from around
12–15% prior to the pivotal trial of this procedure to 5% when
the procedure was carried out by skilled operators. However,
bovine pericardium obtained FDA device approval without
attention to the role of operator competence or its ultimate use in
care. This example draws attention to the lack of focus on
deﬁnitive outcomes and patient oriented outcomes.
Closing Remarks
The FDA applies very different processes to evaluating drugs and
devices. Although the regulatory process for drugs stimulates the
production of good quality evidence of whether the drug improves
outcomes for a particular condition, thismay imply that it is better
than best alternative care or that the results from the clinical trial
population are generalizable to the “real world.” Getting drugs
Table 1 Food and DrugAdministration working deﬁnitions of drugs and
devices
Drugs Articles that are recognized in the Ofﬁcial United States
Pharmacopoeia, or Ofﬁcial National Formulary, or any supplement
to any of them; they are articles (other than food) that are
intended for use in the diagnosis, cure, mitigation, treatment, or
prevention of disease in man or other animals that are intended
to affect the structure or any function of the body.
Devices Articles used in the diagnosis, cure, mitigation, treatment or
prevention of disease or medical condition that affect the
structure or function of the body, but that do not achieve their
intended effect through chemical reaction or metabolism.
Table 2 Regulatory approval processes for devices
Premarket notiﬁcation 510(k) Premarket approval
Standard fees $3,693 $200,725
Small business fee $1,847 ($100 million in gross receipts or sales) $30 million in gross receipts or sales - fee is waived*
$100 million in gross receipts or sales - $50,181*
Review time 90% completed within 90 days Average of 335 days
*For ﬁrst application.
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from discovery to market takes years or even decades. The regu-
latory process for devices, on the other hand, is usually much
faster. Because controlled clinical trials are rare for devices, most
devices come to market with evidence that falls far short of drugs.
The FDA’s approach to evaluating and regulating drugs and
medical devices is dictated by statute. Changes in its approach for
evaluating new medical devices—for example, to ﬁt a compara-
tive effectiveness framework—would require federal legislation.
Because of the uncertainty it would create for the drug and device
industries, wholesale adjustments to the FDA’s current process of
evaluating medical devices is highly unlikely in the foreseeable
future. Therefore, one can expect that the bulk of CER will
continue to be conducted on drugs and devices that have already
been approved for marketing. Conducting CER outside of the
FDA regulatory structure does have the advantage of allowing
for novel study designs and comparisons that could address
important questions in an efﬁcient and potentially timely manner.
On moving forward, we should have great optimism that
the new CER funding offers a unique opportunity to improve
the knowledge base for medications and medical devices. First
and foremost, it is hoped that CER improves patient care. It is
also hoped that the information will help control health-care
costs.
Source of ﬁnancial support: Oxford Outcomes, the National Pharmaceu-
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